Vermillion's OVA1 Test Assigned Category 1 CPT Code; Stock Jumps | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion's shares soared 92 percent to $2.56 in mid-afternoon trade on the Nasdaq today after the firm announced that a panel of the American Medical Association approved the company's application for a Category 1 CPT code for its OVA1 ovarian cancer test.

The new code assigned to OVA1 becomes effective Jan. 1, 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.